193 related articles for article (PubMed ID: 37304239)
21. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
[TBL] [Abstract][Full Text] [Related]
22. HGH1 and the immune landscape: a novel prognostic marker for immune-desert tumor microenvironment identification and immunotherapy outcome prediction in human cancers.
Wu G; Dong Y; Hu Q; Ma H; Xu Q; Xu K; Chen H; Yang Z; He M
Cell Cycle; 2023 Sep; 22(18):1969-1985. PubMed ID: 37811868
[TBL] [Abstract][Full Text] [Related]
23. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
24. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
25. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
26. Pan-cancer analysis reveals RIPK2 predicts prognosis and promotes immune therapy resistance via triggering cytotoxic T lymphocytes dysfunction.
Song J; Yang R; Wei R; Du Y; He P; Liu X
Mol Med; 2022 May; 28(1):47. PubMed ID: 35508972
[TBL] [Abstract][Full Text] [Related]
27. Systematic pan-cancer analysis identifies transmembrane protein 158 as a potential therapeutic, prognostic and immunological biomarker.
Li J; Hou H; Sun J; Ding Z; Xu Y; Li G
Funct Integr Genomics; 2023 Mar; 23(2):105. PubMed ID: 36977915
[TBL] [Abstract][Full Text] [Related]
28. Integrated Analysis of
Du X; Xia W; Fan W; Shen X; Wu H; Zhang H
Dis Markers; 2022; 2022():9365046. PubMed ID: 36118669
[No Abstract] [Full Text] [Related]
29. A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.
Wen J; Mao X; Cheng Q; Liu Z; Liu F
Sci Rep; 2021 Nov; 11(1):22502. PubMed ID: 34795387
[TBL] [Abstract][Full Text] [Related]
30. A systematic pan-cancer analysis identifies LDHA as a novel predictor for immunological, prognostic, and immunotherapy resistance.
Zhang Q; Luo Y; Qian B; Cao X; Xu C; Guo K; Wan R; Jiang Y; Wang T; Mei Z; Liu J; Lv C
Aging (Albany NY); 2024 May; 16(9):8000-8018. PubMed ID: 38709280
[TBL] [Abstract][Full Text] [Related]
31. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
[TBL] [Abstract][Full Text] [Related]
34. Pan-cancer analysis and experimental validation revealed the m6A methyltransferase KIAA1429 as a potential biomarker for diagnosis, prognosis, and immunotherapy.
Ma C; Zheng Q; Wang Y; Li G; Zhao M; Sun Z
Aging (Albany NY); 2023 Aug; 15(17):8664-8691. PubMed ID: 37606975
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Pan-Cancer Analysis of GINS2 for Human Tumour Prognosis and as an Immunological Biomarker.
Meng W; Jiang Z; Zhang X; Cai B; Ma L; Guan Y
Comput Math Methods Med; 2022; 2022():3119721. PubMed ID: 36466552
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
37. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
Zhong A; Chen T; Xing Y; Pan X; Shi M
Front Immunol; 2021; 12():758648. PubMed ID: 34745134
[TBL] [Abstract][Full Text] [Related]
38. The value of
Feng Y; Wang Y; Guo K; Feng J; Shao C; Pan M; Ding P; Liu H; Duan H; Lu D; Wang Z; Zhang Y; Zhang Y; Han J; Li X; Yan X
Ann Transl Med; 2022 Apr; 10(8):466. PubMed ID: 35571400
[TBL] [Abstract][Full Text] [Related]
39. The prognostic value and immunological role of CD44 in pan-cancer study.
Chen S; Zhang S; Chen S; Ma F
Sci Rep; 2023 Apr; 13(1):7011. PubMed ID: 37117249
[TBL] [Abstract][Full Text] [Related]
40. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
